The novel interpretation of the pathophysiology of MFS-related aortopathy based on TGF-β signaling [25] has resulted in researches evaluating the potential of TGF-β-antagonism by ACE-inhibitors and angiotensin II receptor blockers (ARB) [21, 22, 26]. This evidence concerns the gene TGFB1 and Marfan syndrome.